Trial results

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

NCT06161844 on ClinicalTrials.gov · last registry update 2025-07-11

Finished 14 May 2025, after enrolling 506 people. Primary outcome, as filed: Change from baseline to week 32 in glycosylated haemoglobin (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sponsor type

Industry

Enrollment

506

Started

2024-02-23

Primary completion

2025-05-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline to week 32 in glycosylated haemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.